A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 study to Evaluate the Efficacy and Safety of HP-5000 in Subjects with Osteoarthritis (OA) Pain of the Knee
This is a multi-center, randomized, double-blind, and placebo-controlled phase 3 study evaluating the safety and efficacy of HP-5000 in subjects with OA pain of the knees. The study will consist of up to a 28-day Screening Phase that will include a Washout Period of current prescription and over the counter (OTC) analgesics; a 12-week Double-blind Treatment Phase, and a 1-week safety Follow-up Phase.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
370
A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.
A placebo patch without diclofenac sodium was used for the placebo arm.
Applied Research Center of Arkansas
Little Rock, Arkansas, United States
Clinical Research of West Florida,Inc.
Clearwater, Florida, United States
Universal Axon Clinical Research, LLC
Doral, Florida, United States
Change From Baseline to Week 12 in WOMAC Pain Score (Intent-to-treat Set)
To evaluate efficacy of HP-5000 patch treatment compared with HP-5000 placebo patch treatment of Osteoarthritis of the knee as evaluated by change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score from baseline to week 12. WOMAC pain score is a scale that evaluate five items including walking, stair climbing, nocturnal, rest and weight bearing. Each item is rated on a scale of 0 to 4, with 0 being no difficulty and 4 being extremely difficulty. The total score is the sum of five items. The total score ranges from 0 to 20 with a low score considered a better outcome and a high score considered a worse outcome.
Time frame: Baseline and 12-week
Change From Baseline to Week 12 in WOMAC Stiffness Score
To evaluate efficacy of HP-5000 patch treatment compared with HP-5000 placebo patch treatment of Osteoarthritis of the knee as evaluated by change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score from baseline to week 12. WOMAC pain score is a scale that evaluate five items including walking, stair climbing, nocturnal, rest and weight bearing. Each item is rated on a scale of 0 to 4, with 0 being no difficulty and 4 being extremely difficulty. The total score is the sum of five items. The total score ranges from 0 to 20 with a low score considered a better outcome and a high score considered a worse outcome.
Time frame: 12 weeks
WOMAC Physical Function Change From Baseline at Week 12
To evaluate efficacy of HP-5000 patch treatment compared with HP-5000 placebo patch treatment of Osteoarthritis of the knee as evaluated by change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score from baseline to week 12. WOMAC pain score is a scale that evaluate five items including walking, stair climbing, nocturnal, rest and weight bearing. Each item is rated on a scale of 0 to 4, with 0 being no difficulty and 4 being extremely difficulty. The total score is the sum of five items. The total score ranges from 0 to 20 with a low score considered a better outcome and a high score considered a worse outcome.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Arthritis and Diabetes Clinic, Inc.
Monroe, Louisiana, United States
Noven Pharmaceuticals, Inc.
Jersey City, New Jersey, United States
Velocity Clinical Research
Cincinnati, Ohio, United States
Partners in Clinical Research
Cumberland, Rhode Island, United States
Palmetto Clinical Research
Summerville, South Carolina, United States
Metroplex Clinical Research Center
Dallas, Texas, United States
Quality Research Inc.
San Antonio, Texas, United States
Time frame: Baseline and 12 weeks